Inflammation and fibrogenesis in steatohepatitis (Q37981867)

26 August 2017

Inflammation and fibrogenesis in steatohepatitis (English)

1 reference

26 August 2017

0 references

0 references

Hideki Fujii

1

1 reference

PubMed ID

22310735

26 August 2017

Norifumi Kawada

series ordinal

2

1 reference

26 August 2017

7 February 2012

1 reference

Journal of Gastroenterology

26 August 2017

1 reference

26 August 2017

47

1 reference

26 August 2017

3

1 reference

26 August 2017

215-225

1 reference

Epidemiology and natural history of non-alcoholic steatohepatitis

26 August 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Nonalcoholic fatty liver disease: pathology and pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Hepatic steatosis: innocent bystander or guilty party?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Oxidative stress and oval cell accumulation in mice and humans with alcoholic and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Mechanisms of disease progression in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Insulin resistance in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Causes and metabolic consequences of Fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: Role of insulin resistance and hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Beta-cell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Ethanol and fish oil induce NFkappaB transactivation of the collagen alpha2(I) promoter through lipid peroxidation-driven activation of the PKC-PI3K-Akt pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Evolution of hepatic fibrosis research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Role of adipocytokines in hepatic fibrogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Adipokines and the peripheral and neural control of energy balance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Fibrogenesis in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Cell signaling. Fat stress and liver resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Lipopolysaccharides in liver injury: molecular mechanisms of Kupffer cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Tumour necrosis factor alpha signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Visceral fat: a key mediator of steatohepatitis in metabolic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

The role of leptin in human obesity and disease: a review of current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Leptin is essential for the hepatic fibrogenic response to chronic liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Influence of leptin in the development of hepatic fibrosis produced in mice by Schistosoma mansoni infection and by chronic carbon tetrachloride administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Reduced nicotinamide adenine dinucleotide phosphate oxidase mediates fibrotic and inflammatory effects of leptin on hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Serum leptin levels in patients with viral chronic hepatitis or liver cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Leptin in Relation to Hepatocellular Carcinoma in Patients with Liver Cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Adiponectin and its receptors in non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Decreased serum adiponectin: an early event in pediatric nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Influence of insulin resistance and adipokines in the grade of steatosis of nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Beyond insulin resistance in NASH: TNF-alpha or adiponectin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

The hormone resistin links obesity to diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Regulation of fasted blood glucose by resistin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Adenovirus-mediated high expression of resistin causes dyslipidemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Resistin as an intrahepatic cytokine: overexpression during chronic injury and induction of proinflammatory actions in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Systemic markers of lipid peroxidation and antioxidants in patients with nonalcoholic Fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

In situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic fatty liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Activation of the phagocyte NADPH oxidase by Rac Guanine nucleotide exchange factors in conjunction with ATP and nucleoside diphosphate kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

The role of Kupffer cell oxidant production in early ethanol-induced liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

21 January 2018

NOX in liver fibrosis

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Involvement of NADPH oxidase isoforms and Src family kinases in CD95-dependent hepatocyte apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

NADPH oxidase in the liver: defensive, offensive, or fibrogenic?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Mitochondrial dysfunction in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Non-alcoholic fatty liver disease pathogenesis: the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Peroxisomal lipid metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Hepatic cytochrome P450 2E1 activity in nondiabetic patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Mitochondrial beta-oxidation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Overexpression of liver-specific cytochrome P4502E1 impairs hepatic insulin signaling in a transgenic mouse model of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Mechanisms and clinical implications of hepatocyte lipoapoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

A novel diagnostic biomarker panel for obesity-related nonalcoholic steatohepatitis (NASH).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

A new composite model including metabolic syndrome, alanine aminotransferase and cytokeratin-18 for the diagnosis of non-alcoholic steatohepatitis in morbidly obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Noninvasive assessment of liver disease severity with liver fat score and CK-18 in NAFLD: Prognostic value of liver fat equation goes beyond hepatic fat estimation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Liver fibrogenesis: a new role for the renin-angiotensin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Angiotensin II participates in hepatic inflammation and fibrosis through MCP-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

TLR4 enhances TGF-beta signaling and hepatic fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Exposure to bacterial cell wall products triggers an inflammatory phenotype in hepatic stellate cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Toll-like receptors and adaptor molecules in liver disease: update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Review article: nuclear receptors and liver disease--current understanding and new therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Nuclear receptors as new perspective for the management of liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

A model of insulin resistance and nonalcoholic steatohepatitis in rats: role of peroxisome proliferator-activated receptor-alpha and n-3 polyunsaturated fatty acid treatment on liver injury.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Effects of n-3 polyunsaturated fatty acids from seal oils on nonalcoholic fatty liver disease associated with hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Omega-3 fatty acid supplementation decreases liver fat content in polycystic ovary syndrome: a randomized controlled trial employing proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Anti-inflammatory actions of PPAR ligands: new insights on cellular and molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Therapeutic trials in nonalcoholic steatohepatitis: insulin sensitizers and related methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Farnesoid X receptor is essential for normal glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Modulation of the endocannabinoid system in cardiovascular disease: therapeutic potential and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Antifibrogenic role of the cannabinoid receptor CB2 in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Mouse patatin-like phospholipase domain-containing 3 influences systemic lipid and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Genome-wide association analysis identifies variants associated with nonalcoholic fatty liver disease that have distinct effects on metabolic traits

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-012-0527-X

Visceral Fat Adipokine Secretion Is Associated With Systemic Inflammation in Obese Humans

21 January 2018

1 reference

12 December 2020

Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis

1 reference

12 December 2020

Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression

1 reference

12 December 2020

Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation

1 reference

12 December 2020

Hypoadiponectinemia accelerates hepatic tumor formation in a nonalcoholic steatohepatitis mouse model

1 reference

12 December 2020

Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor

1 reference

12 December 2020

The natural history of nonalcoholic fatty liver disease: a clinical histopathological study

1 reference

12 December 2020

Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress.

1 reference

12 December 2020

Role of leptin in immunology

1 reference

12 December 2020

Natural history of NAFLD: remarkably benign in the absence of cirrhosis

1 reference

12 December 2020

Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients

1 reference

12 December 2020

Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?

1 reference

12 December 2020

Adipokines and cytokines in non-alcoholic fatty liver disease

1 reference

12 December 2020

CB1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis

1 reference

12 December 2020

Correlation of serum TNF-alpha levels and histologic liver injury scores in pediatric nonalcoholic fatty liver disease

1 reference

12 December 2020

Burning hepatic fat: therapeutic potential for liver-specific thyromimetics in the treatment of nonalcoholic fatty liver disease

1 reference

12 December 2020

Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease

1 reference

12 December 2020

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

1 reference

12 December 2020

In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease

1 reference

12 December 2020

Angiotensin II induces contraction and proliferation of human hepatic stellate cells

1 reference

12 December 2020

Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Angiotensin II stimulates the nuclear translocation of Smad2 and induces PAI-1 mRNA in rat hepatic stellate cells

1 reference

12 December 2020

Cytokines and renin-angiotensin system signaling in hepatic fibrosis

1 reference

12 December 2020

Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis

1 reference

12 December 2020

Nuclear receptor-dependent bile acid signaling is required for normal liver regeneration

1 reference

12 December 2020

Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation

1 reference

12 December 2020

Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis

1 reference

12 December 2020

Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin

1 reference

12 December 2020

10.1007/S00535-012-0527-X

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22310735